ISSN:
0021-9304
Schlagwort(e):
bone defect filler
;
transforming growth factor-β1
;
release kinetics
;
in vivo efficacy
;
pharmacokinetics
;
Chemistry
;
Polymer and Materials Science
Quelle:
Wiley InterScience Backfile Collection 1832-2000
Thema:
Medizin
,
Technik allgemein
Notizen:
Tricalcium phosphate (TCP) was combined with amylopectin to form a deliverable carrier paste for recombinant human transforming growth factor β1 (rhTGF-β1) intended for bone repair applications. Approximately 80% of rhTGF-β1 was released from the carrier within 24 h following in vitro incubation in serum. Full biological activity was maintained, suggesting the growth factor was stable in this formulation before and after in vitro release. In vivo efficacy also was assessed, in comparison to a sham control group and a placebo-treated group, using a rabbit unilateral segmental defect model (1 cm). Radiographs of defect sites taken at scheduled intervals and the mechanical testing of treated limbs at 56 days demonstrated a higher incidence of radiographic bone union, in concert with a stronger torque strength, in the rhTGF-β1-treated group compared to the placebo group. The short duration of the study and the fact that the model used was not a critical defect may account for the lack of superiority of the rhTGF-β1-treated group over the healing of the sham control. The in vivo pharmacokinetics of the growth factor evaluated in the same rabbit model suggested that rhTGF-β1 persisted intact at the defect site for more than 21 days. Gamma imaging and radioactivity recovery at defects administered to [131I]- and [125I]-labeled rhTGF-β1, respectively, estimated the half-life of rhTGF-β1 eliminated from the applied site to be 4-6 days. The present report substantiates the potential of rhTGF-β1 and its carrier for treatment of bone defects. © 1997 John Wiley & Sons, Inc. J Biomed Mater Res., 36, 295-305, 1997.
Zusätzliches Material:
5 Ill.
Materialart:
Digitale Medien
Permalink
